Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

4.5K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.5K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

789
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
789
Long-term Potentiation01:35

Long-term Potentiation

59.2K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
59.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does citing early SIDS research skew contemporary conclusions?

Forensic science, medicine, and pathology·2024
Same author

Identification of an Intravenous Injectable NK1 Receptor Antagonist for Use in Traumatic Brain Injury.

International journal of molecular sciences·2024
Same author

NK1 tachykinin receptor antagonist treatment reduces cerebral edema and intracranial pressure in an ovine model of ischemic stroke.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2024
Same author

Chronic traumatic encephalopathy (CTE)-features and forensic considerations.

Forensic science, medicine, and pathology·2023
Same author

Investigating genetic variants in microRNA regulators of Neurokinin-1 receptor in sudden infant death syndrome.

Acta paediatrica (Oslo, Norway : 1992)·2022
Same author

Chronic traumatic encephalopathy: genes load the gun and repeated concussion pulls the trigger.

Neural regeneration research·2022

Related Experiment Video

Updated: Mar 12, 2026

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
04:48

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

9.8K

Magnesium in the CNS: recent advances and developments.

Robert Vink1

  • 1Sansom Institute for Health Research, University of South Australia, Adelaide, Australia 5000.

Magnesium Research
|November 11, 2016
PubMed
Summary

Magnesium shows neuroprotective potential for brain conditions, but clinical use is limited by poor blood-brain barrier penetration. Novel delivery methods like carriers or permeable salts may improve efficacy and reduce side effects.

Keywords:
alcoholamyloidblood brain barrierinflammationmagnesiumtreatment

More Related Videos

Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation
08:34

Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation

Published on: June 17, 2025

1.2K
Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
11:51

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

31.6K

Related Experiment Videos

Last Updated: Mar 12, 2026

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
04:48

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

9.8K
Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation
08:34

Assessing Microglial Phagocytosis of Myelin Debris in vitro Under Repeated Magnetic Stimulation

Published on: June 17, 2025

1.2K
Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
11:51

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

31.6K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurology

Background:

  • Magnesium's neuroprotective role in neurological diseases has been recognized for decades.
  • Despite evidence, clinical translation remains challenging due to poor blood-brain barrier (BBB) penetration.
  • Magnesium is implicated in various neurological conditions, including Alzheimer's, Parkinson's, and acute brain injury.

Purpose of the Study:

  • To review the challenges and potential strategies for enhancing magnesium's therapeutic efficacy in neurological disorders.
  • To explore methods for improving central nervous system (CNS) penetration of magnesium compounds.
  • To identify approaches that minimize peripheral side effects associated with magnesium administration.

Main Methods:

  • Review of experimental evidence and studies on magnesium delivery across the BBB.
  • Investigation of carrier-mediated transport systems (e.g., polyethylene glycol).
  • Evaluation of alternative magnesium salts with enhanced permeability (e.g., magnesium threonate).

Main Results:

  • Simple magnesium salt administration often fails due to insufficient BBB penetration.
  • Carrier molecules like polyethylene glycol can improve CNS delivery and reduce required magnesium dosage.
  • Magnesium threonate shows promise for chronic neurological conditions, with positive outcomes in Alzheimer's disease models.
  • Improved central penetration of magnesium compounds can mitigate peripheral side effects.

Conclusions:

  • Enhancing magnesium's CNS penetration is crucial for effective neuroprotection.
  • Carrier systems and permeable magnesium salts offer promising strategies to overcome delivery challenges.
  • Further investigation in relevant animal models is needed to validate these approaches for human conditions.